Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
209.55B
Market cap209.55B
Price-Earnings ratio
13.04
Price-Earnings ratio13.04
Dividend yield
3.78%
Dividend yield3.78%
Average volume
12.30M
Average volume12.30M
High today
$84.80
High today$84.80
Low today
$83.54
Low today$83.54
Open price
$84.27
Open price$84.27
Volume
6.73M
Volume6.73M
52 Week high
$119.38
52 Week high$119.38
52 Week low
$73.31
52 Week low$73.31

MRK News

Seeking Alpha 2h
Merck to cancel London drug research center, lay off scientists : FT

Merck (NYSE:MRK) has canceled plans for a £1B research center in London and will lay off over 100 scientists, the Financial Times reported on Wednesday. This d...

Merck to cancel London drug research center, lay off scientists : FT
TipRanks 4h
Merck scraps London drug research center, cuts 125 staff, FT reports

Merck (MRK) plans to lay off more than 100 scientific staff as it scraps its GBP 1B research center in London, The Financial Times’ Hannah Kuchler and Patrick T...

TipRanks 23h
Merck & Co. Closes $6 Billion Notes Offering

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

Analyst ratings

59%

of 27 ratings
Buy
59.3%
Hold
40.7%
Sell
0%

More MRK News

Simply Wall St 2d
Merck Gains Breakthrough Therapy Designation For Lung Cancer Drug

recently presented promising phase 2 trial results for ifinatamab deruxtecan, earning Breakthrough Therapy Designation from multiple regulatory bodies, an event...

Merck Gains Breakthrough Therapy Designation For Lung Cancer Drug
Benzinga 2d
Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences

Summit Therapeutics Inc. SMMT, on Sunday, revealed the updated overall survival (OS) results from the global Phase 3 HARMONi trial of ivonescimab at the 2025 Wo...

Summit Therapeutics' Lung Cancer Drug Under Dark Clouds As Keytruda Challenger Shows Regional Data Differences
Simply Wall St 2d
What Merck's Latest Oncology and Cardiovascular Trial Results Mean For Shareholders

In the past week, Merck and Daiichi Sankyo reported that ifinatamab deruxtecan showed clinically meaningful response rates in previously treated extensive-stage...

What Merck's Latest Oncology and Cardiovascular Trial Results Mean For Shareholders
TipRanks 3d
Daiichi, Merck announce results from phase 2 trial of ifinatamab deruxtecan

Results from the IDeate-Lung01 phase 2 trial showed that ifinatamab deruxtecan demonstrated clinically meaningful response rates in patients with previously tre...

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.